BioVie Inc. - Common stock (BIVI)
BIVI moved a median of -0.84% 30 minutes after news, and -1.44% by the close. How BIVI actually reacts to news — the realized, point-in-time move the market made, measured across 798 labeled events over the last three years with zero look-ahead.
BIVI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.47% | 28% | 759 |
| 30-min | -0.84% | 36% | 796 |
| 60-min | -0.92% | 35% | 796 |
| to close | -1.44% | 40% | 790 |
| Middle 50% of BIVI reactions | -3.24% to +0.81% |
|---|---|
| Median reaction (30-min) | -0.84% |
| Measured reactions | 798 |
Half of all BioVie Inc. - Common stock news events land between -3.24% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BIVI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BIVI's baseline. Nothing else.
Recent BIVI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting | Press release | GlobeNewswire | +4.17% | -3.33% | |
| New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn | Press release | ACCESS Newswire | +2.21% | -6.38% | |
| Form DEF 14A BIOVIE INC. For: Sep 28 | SEC filing · Form DEF | SEC EDGAR | +1.94% | -0.65% | |
| New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global | Press release | ACCESS Newswire | +1.21% | -1.91% | |
| New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global | Press release | ACCESS Newswire | +1.22% | -0.61% | |
| Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results | Press release | ACCESS Newswire | -3.98% | -2.27% | |
| BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | Press release | GlobeNewswire | -0.79% | -7.89% | |
| BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid | Press release | GlobeNewswire | -0.79% | -7.89% | |
| Form 8-K BIOVIE INC. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +7.89% | |
| BioVie Announces Update to Parkinson’s Phase 3 Development Program | Press release | GlobeNewswire | +1.46% | +0.98% | |
| BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | Press release | GlobeNewswire | -2.11% | -4.60% | |
| New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET | Press release | ACCESS Newswire | -2.19% | +16.94% | |
| Form S-1/A BIOVIE INC. | SEC filing · Form S-1 | SEC EDGAR | +8.27% | -12.03% | |
| Form 10-K BIOVIE INC. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -2.73% | -6.02% | |
| New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results | Press release | ACCESS Newswire | +5.60% | — | |
| Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results | Press release | ACCESS Newswire | -10.65% | -18.09% | |
| BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease | Press release | GlobeNewswire | -16.67% | -0.73% | |
| Form 8-K BIOVIE INC. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -16.67% | -0.73% | |
| Form S-1/A BIOVIE INC. | SEC filing · Form S-1 | SEC EDGAR | -16.67% | -0.73% | |
| Form S-1/A BIOVIE INC. | SEC filing · Form S-1 | SEC EDGAR | +4.67% | +8.00% | |
| Form S-1 BIOVIE INC. | SEC filing · Form S-1 | SEC EDGAR | +3.50% | +1.06% | |
| Form EFFECT BIOVIE INC. | SEC filing · Form EFFECT | SEC EDGAR | -1.96% | -4.90% | |
| Form S-3 BIOVIE INC. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +8.38% | |
| Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | +0.00% | +1.27% | |
| Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +0.00% | -2.74% | |
| Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 | Press release | GlobeNewswire | -0.69% | +2.78% | |
| BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | Press release | GlobeNewswire | -1.27% | -8.86% | |
| BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease | Press release | GlobeNewswire | +0.00% | +3.82% | |
| Form 10-Q BIOVIE INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.52% | -7.04% | |
| BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 | Press release | GlobeNewswire | -1.83% | +5.30% | |
| BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting | Press release | GlobeNewswire | +2.19% | +6.57% | |
| BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 | Press release | GlobeNewswire | +0.00% | +1.46% | |
| Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4 | Press release | GlobeNewswire | -2.57% | -0.79% | |
| BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting | Press release | GlobeNewswire | +2.59% | -4.31% | |
| Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | GlobeNewswire | -0.90% | +0.00% | |
| Form 10-Q BIOVIE INC. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.38% | +6.42% | |
| BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease | Press release | GlobeNewswire | -1.46% | -5.11% | |
| HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS | Press release | PR Newswire | — | +0.00% | |
| Form S-8 BIOVIE INC. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +5.84% | |
| Form EFFECT BIOVIE INC. | SEC filing · Form EFFECT | SEC EDGAR | -2.07% | -5.52% | |
| Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9 | Press release | GlobeNewswire | -2.07% | -5.52% | |
| Form 8-K BIOVIE INC. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | — | |
| Form 10-Q BIOVIE INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.86% | -1.95% | |
| Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | -1.51% | -2.08% | |
| Form POS AM BIOVIE INC. | SEC filing · Form POS | SEC EDGAR | -1.00% | -6.03% | |
| Form POS EX BIOVIE INC. | SEC filing · Form POS | SEC EDGAR | -1.00% | -6.03% | |
| BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +1.50% | +2.76% | |
| BioVie to Host Live Investor Webinar and Q&A on Oct. 8 | Press release | GlobeNewswire | +1.50% | +2.76% | |
| Form DEF 14A BIOVIE INC. For: Sep 25 | SEC filing · Form DEF | SEC EDGAR | +1.50% | +2.76% | |
| Form 10-K BIOVIE INC. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -0.59% | +4.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BIVI section they belong to.
Where else BIVI is measured.
BIVI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TESARO (TSRO) | 804 | -0.14% | 47% |
| SYNERGY PHARMACEUTICALS (SGYP) | 803 | -0.38% | 41% |
| Sanofi - American Depositary Shares (SNY) | 798 | +0.02% | 52% |
| Cerecor, Inc (CERC) | 795 | -0.03% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioVie Inc. - Common stock's median reaction calculated?
Every labeled BIVI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 798 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of BIVI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BIVI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.